NCT02238756已完成1 期
Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- CureVac
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Number of subjects with serious and non serious adverse events
研究概览
简要总结
The purpose of this clinical trial is to investigate the safety and tolerability of IM administered CV8102 and an IM administered combination of CV8102 and rabies vaccine in humans.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Compliant with protocol procedures and available for clinical F/U until the protocol-defined end of the trial
- •Physical examination and laboratory results without clinically significant findings
- •Body Mass Index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2
- •Subjects must use reliable forms of contraception (barrier method with spermicidal agent or true abstinence) and must refrain from sperm donation during treatment and the 4-week F/U period after the last treatment.
排除标准
- •Use of any investigational or non-registered product (adjuvant, drug) other than CV8102 within 4 weeks preceding the administration of the CV8102, or planned use of any such agent during the trial period
- •Subject has received any licensed or non-licensed vaccines within 4 weeks prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine or planned vaccinations during the trial period
- •Any treatment with immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine. The use of inhaled and nasal steroids, as well as topical steroids outside the vaccination area, will be permitted
- •Any medically diagnosed or suspected immune deficient condition based on medical history and physical examination
- •History of autoimmune disease or suspected autoimmune disease based on medical history and physical examination that cannot be ruled out based on further examinations
- •Administration of immunoglobulins (Igs) and/or any blood products within the 3 months preceding the administration of CV8102 or licensed rabies vaccine
- •Acute disease at the time of enrolment. Acute disease is defined as the presence of any acute condition including but not limited to non-febrile or febrile common colds, urinary tract infections, inflammatory, allergic or traumatic conditions that may interfere with safety assessment of the investigational products
- •Presence or evidence of significant acute or chronic disease, in particular heart disease including coronary artery disease and chronic pulmonary diseases (e.g., chronic obstructive pulmonary disease [COPD]); uncontrolled medical or psychiatric illness (subjects with uncomplicated chronic diagnoses stable and treated for ≥ 3 months e.g., mild hypertension well-controlled with medication, may be enrolled - provided the condition and its therapy are known not to be associated with an immunocompromised state or an autoimmune disease)
- •Major congenital defects
- •Known allergy to any component (or closely related substance) of the licensed rabies vaccine product
- •Known type I allergy to beta-lactam antibiotics
- •Evidence of current alcohol or drug abuse
- •History of any neurological disorders or seizures
- •Known seropositivity for human immunodeficiency virus (HIV), hepatitis B virus (HBV) (except in subjects previously vaccinated against HBV) or hepatitis C virus (HCV)
- •Foreseeable non-compliance with protocol as judged by the Investigator
- •History of any life-threatening anaphylactic reactions
- •Subjects with impaired coagulation in whom an IM injection is contraindicated.
- •Additional exclusion criteria for subjects participating in the (adjuvanted) rabies vaccination part:
- •Subject has previously received any investigational or licensed rabies vaccine
- •Intending to travel to regions/countries for which rabies vaccinations are recommended or where high risk of infection exists according to travel recommendations by the German Society of Tropical Medicine and International Health (DTG) during the trial and F/U period
- •Subject is taking chloroquine for malaria treatment or prophylaxis.
研究组 & 干预措施
Rabipur
Active Comparator
干预措施: Rabipur (Biological)
CV8102 + Rabipur
Experimental
干预措施: CV8102 + Rabipur (Biological)
CV8102
Experimental
干预措施: CV8102 (Biological)
结局指标
主要结局
Number of subjects with serious and non serious adverse events
时间窗: Up to 12 months
次要结局
- Maximum tolerated dose (MTD) of CV8102 within the dose range of 25 µg to 250 µg.(Up to day 49)
- MTD of CV8102 in combination with rabies vaccine(Up to Day 49)
- Vaccination-elicited serum rabies VNTs among the dose groups(Up to day 35)
- Vaccination-elicited innate and adaptive immune responses(Up to Day 35)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1Myotonic Dystrophy 1NCT06204809PepGen Inc24
尚未招募
1 期
A Phase I Clinical Trial of JH013 InjectionHealthy Subjects (HS)NCT06633055Biotech Pharmaceutical Co., Ltd.32
Unknown
1 期
Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)Ischemic StrokeNCT04590118Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.60
已完成
1 期
Evaluation of LBL-003 Phase I Study in Patients With Advanced MalignanciesAdvanced Malignant TumorNCT05042908Nanjing Leads Biolabs Co.,Ltd18
已完成
1 期
Safety Study of GMDTC Injection in Healthy ParticipantsCadmium ExposureNCT05908383Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd.76